235 related articles for article (PubMed ID: 21343392)
1. Peroxiredoxin 1 controls prostate cancer growth through Toll-like receptor 4-dependent regulation of tumor vasculature.
Riddell JR; Bshara W; Moser MT; Spernyak JA; Foster BA; Gollnick SO
Cancer Res; 2011 Mar; 71(5):1637-46. PubMed ID: 21343392
[TBL] [Abstract][Full Text] [Related]
2. Peroxiredoxin 1 stimulates endothelial cell expression of VEGF via TLR4 dependent activation of HIF-1α.
Riddell JR; Maier P; Sass SN; Moser MT; Foster BA; Gollnick SO
PLoS One; 2012; 7(11):e50394. PubMed ID: 23185615
[TBL] [Abstract][Full Text] [Related]
3. Peroxiredoxin 1-mediated activation of TLR4/NF-κB pathway contributes to neuroinflammatory injury in intracerebral hemorrhage.
Liu DL; Zhao LX; Zhang S; Du JR
Int Immunopharmacol; 2016 Dec; 41():82-89. PubMed ID: 27821296
[TBL] [Abstract][Full Text] [Related]
4. Prx1 promotes the proliferation and migration of vascular smooth muscle cells in a TLR4-dependent manner.
Zhu Z; Zheng X; Li D; Wang T; Xu R; Piao H; Liu K
Mol Med Rep; 2017 Jan; 15(1):345-351. PubMed ID: 27922677
[TBL] [Abstract][Full Text] [Related]
5. Peroxiredoxin 1 stimulates secretion of proinflammatory cytokines by binding to TLR4.
Riddell JR; Wang XY; Minderman H; Gollnick SO
J Immunol; 2010 Jan; 184(2):1022-30. PubMed ID: 20018613
[TBL] [Abstract][Full Text] [Related]
6. Prx1 enhances androgen receptor function in prostate cancer cells by increasing receptor affinity to dihydrotestosterone.
Chhipa RR; Lee KS; Onate S; Wu Y; Ip C
Mol Cancer Res; 2009 Sep; 7(9):1543-52. PubMed ID: 19737972
[TBL] [Abstract][Full Text] [Related]
7. Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumorigenicity.
Hua D; Liu MY; Cheng ZD; Qin XJ; Zhang HM; Chen Y; Qin GJ; Liang G; Li JN; Han XF; Liu DX
Mol Immunol; 2009 Sep; 46(15):2876-84. PubMed ID: 19643479
[TBL] [Abstract][Full Text] [Related]
8. Toll-like receptor 4 promotes angiogenesis in pancreatic cancer via PI3K/AKT signaling.
Sun Y; Wu C; Ma J; Yang Y; Man X; Wu H; Li S
Exp Cell Res; 2016 Oct; 347(2):274-82. PubMed ID: 27426724
[TBL] [Abstract][Full Text] [Related]
9. Angiogenesis and prostate cancer: identification of a molecular progression switch.
Huss WJ; Hanrahan CF; Barrios RJ; Simons JW; Greenberg NM
Cancer Res; 2001 Mar; 61(6):2736-43. PubMed ID: 11289156
[TBL] [Abstract][Full Text] [Related]
10. Pristimerin Inhibits Prostate Cancer Bone Metastasis by Targeting PC-3 Stem Cell Characteristics and VEGF-Induced Vasculogenesis of BM-EPCs.
Huang S; He P; Peng X; Li J; Xu D; Tang Y
Cell Physiol Biochem; 2015; 37(1):253-68. PubMed ID: 26302893
[TBL] [Abstract][Full Text] [Related]
11. Peroxiredoxin 1 interacts with androgen receptor and enhances its transactivation.
Park SY; Yu X; Ip C; Mohler JL; Bogner PN; Park YM
Cancer Res; 2007 Oct; 67(19):9294-303. PubMed ID: 17909037
[TBL] [Abstract][Full Text] [Related]
12. Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands.
West XZ; Malinin NL; Merkulova AA; Tischenko M; Kerr BA; Borden EC; Podrez EA; Salomon RG; Byzova TV
Nature; 2010 Oct; 467(7318):972-6. PubMed ID: 20927103
[TBL] [Abstract][Full Text] [Related]
13. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease.
Kaushal V; Mukunyadzi P; Dennis RA; Siegel ER; Johnson DE; Kohli M
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):584-93. PubMed ID: 15701844
[TBL] [Abstract][Full Text] [Related]
14. Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells.
Ferrer FA; Miller LJ; Andrawis RI; Kurtzman SH; Albertsen PC; Laudone VP; Kreutzer DL
Urology; 1998 Jan; 51(1):161-7. PubMed ID: 9457313
[TBL] [Abstract][Full Text] [Related]
15. Differences in Proinflammatory Property of Six Subtypes of Peroxiredoxins and Anti-Inflammatory Effect of Ligustilide in Macrophages.
Zhao LX; Du JR; Zhou HJ; Liu DL; Gu MX; Long FY
PLoS One; 2016; 11(10):e0164586. PubMed ID: 27716839
[TBL] [Abstract][Full Text] [Related]
16. MMAC/PTEN tumor suppressor gene regulates vascular endothelial growth factor-mediated angiogenesis in prostate cancer.
Koul D; Shen R; Garyali A; Ke LD; Liu TJ; Yung WK
Int J Oncol; 2002 Sep; 21(3):469-75. PubMed ID: 12168088
[TBL] [Abstract][Full Text] [Related]
17. The Ron receptor tyrosine kinase positively regulates angiogenic chemokine production in prostate cancer cells.
Thobe MN; Gurusamy D; Pathrose P; Waltz SE
Oncogene; 2010 Jan; 29(2):214-26. PubMed ID: 19838218
[TBL] [Abstract][Full Text] [Related]
18. 1'-Acetoxychavicol acetate suppresses angiogenesis-mediated human prostate tumor growth by targeting VEGF-mediated Src-FAK-Rho GTPase-signaling pathway.
Pang X; Zhang L; Lai L; Chen J; Wu Y; Yi Z; Zhang J; Qu W; Aggarwal BB; Liu M
Carcinogenesis; 2011 Jun; 32(6):904-12. PubMed ID: 21427164
[TBL] [Abstract][Full Text] [Related]
19. S100A9 interaction with TLR4 promotes tumor growth.
Källberg E; Vogl T; Liberg D; Olsson A; Björk P; Wikström P; Bergh A; Roth J; Ivars F; Leanderson T
PLoS One; 2012; 7(3):e34207. PubMed ID: 22470535
[TBL] [Abstract][Full Text] [Related]
20. Endothelial immune activation programmes cell-fate decisions and angiogenesis by inducing angiogenesis regulator DLL4 through TLR4-ERK-FOXC2 signalling.
Xia S; Menden HL; Korfhagen TR; Kume T; Sampath V
J Physiol; 2018 Apr; 596(8):1397-1417. PubMed ID: 29380370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
